Psychopharmacology Practice Questions

Q: Which of the following antidepressants is used in atypical depression?

Phenelzine. **Explanation:** **Atypical depression** is a subtype of Major Depressive Disorder characterized by **mood reactivity** (the ability to feel better in response to positive events) along with at least two of the following: increased appetite/weight gain, hypersomnia, leaden paralysis (heavy feeling in limbs), and a long-standing pattern of interpersonal rejection sensitivity. **Why Phenelzine is correct:** Historically and clinically, **Monoamine Oxidase Inhibitors (MAOIs)** like **Phenelzine**, Tranylcypromine, and Isocarboxazid are considered the most effective treatments for atypical depression. While Selective Serotonin Reuptake Inhibitors (SSRIs) are now used as first-line therapy due to a better safety profile, MAOIs remain the "gold standard" in terms of efficacy for this specific subtype, especially in treatment-resistant cases. **Why the other options are incorrect:** * **Imipramine & Amitriptyline (Options A & D):** These are **Tricyclic Antidepressants (TCAs)**. TCAs are generally less effective for atypical depression compared to MAOIs and often exacerbate symptoms like weight gain and sedation, which are already present in atypical presentations. * **Paroxetine (Option C):** This is an **SSRI**. While SSRIs are commonly used in clinical practice for atypical depression due to fewer side effects, they are not the "classic" or superior choice when compared to the historical efficacy of MAOIs in this specific context. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** SSRIs are first-line (due to safety), but MAOIs (Phenelzine) are the most effective. * **Dietary Restriction:** Patients on Phenelzine must avoid **Tyramine-rich foods** (aged cheese, wine) to prevent a **Hypertensive Crisis**. * **Key Feature:** Mood reactivity is the pathognomonic feature of atypical depression.

Q: Which of the following medications is least effective against depression?

Valproate. **Explanation:** In the management of Bipolar Disorder, medications are categorized based on their efficacy in treating mania, depression, or both. **Valproate (Option A)** is a potent anti-manic agent and a first-line stabilizer for rapid cycling and mixed episodes. However, it has **minimal to no proven efficacy** in treating acute bipolar depression. While it may help prevent future depressive episodes as a maintenance therapy, it is the least effective among the choices for active depressive symptoms. **Why the other options are incorrect:** * **Lamotrigine (Option B):** This is the "gold standard" for preventing bipolar depression. While it is not used for acute mania, it has significant antidepressant properties and is specifically indicated for the maintenance of Bipolar II disorder. * **Lithium (Option C):** The classic mood stabilizer. It has established efficacy in treating acute bipolar depression (though slower than antipsychotics) and is the only medication proven to reduce the risk of suicide in these patients. * **Aripiprazole (Option D):** An atypical antipsychotic that is FDA-approved as an adjunctive treatment for Major Depressive Disorder (MDD) and is effective in managing bipolar symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Acute Mania:** Lithium or Valproate. * **DOC for Bipolar Depression:** Quetiapine, Lurasidone, or Olanzapine-Fluoxetine combination (OFC). * **Lithium** is unique for its **anti-suicidal** properties. * **Lamotrigine** carries a risk of **Stevens-Johnson Syndrome (SJS)**; hence, it requires slow dose titration.

Q: What is the usual adult maintenance dose of Clozapine?

300 mg. **Explanation:** Clozapine is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. The correct answer is **300 mg**, as this represents the standard target maintenance dose for most adult patients to achieve therapeutic efficacy. **1. Why 300 mg is Correct:** The initiation of Clozapine requires slow titration to minimize side effects like orthostatic hypotension and seizures. While the starting dose is 12.5 mg once or twice daily, it is gradually increased by 25–50 mg/day. The **usual adult maintenance dose** typically ranges between **300 mg and 450 mg per day** (administered in divided doses). 300 mg is the established clinical benchmark for the lower end of the effective maintenance range. **2. Analysis of Incorrect Options:** * **150 mg (Option A):** This is generally considered a sub-therapeutic dose for maintenance in most adults, though it may be used during the titration phase or in elderly/sensitive patients. * **250 mg (Option B):** While closer to the target, it is still slightly below the standard 300–450 mg maintenance range defined in most pharmacological guidelines (e.g., Maudsley, FDA). * **500 mg (Option D):** While some patients require up to 600–900 mg (maximum limit), 500 mg is above the "usual" starting maintenance point and carries a higher risk of dose-dependent seizures. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Treatment-resistant schizophrenia (failure of ≥2 antipsychotics, one being an atypical). * **Black Box Warning:** **Agranulocytosis** (requires mandatory WBC and ANC monitoring). * **Side Effects:** Sialorrhea (excessive salivation), sedation, weight gain, and lowering of the seizure threshold. * **Myocarditis:** A rare but fatal side effect; monitor for chest pain or tachycardia in the first month. * **Therapeutic Range:** Plasma levels >350 ng/mL are generally required for a response.

Q: What is the most common congenital anomaly associated with lithium use during pregnancy?

Cardiac malformations. **Explanation:** **1. Why Cardiac Malformations are Correct:** Lithium is a known teratogen, particularly when administered during the first trimester of pregnancy. While the absolute risk is lower than previously thought, the most common category of anomalies associated with lithium use is **cardiac malformations**. Specifically, lithium is classically associated with **Ebstein’s Anomaly**, a rare defect characterized by the downward displacement of the tricuspid valve into the right ventricle ("atrialization" of the ventricle). While Ebstein’s is the most *specific* association, general cardiac septal defects are numerically more common in lithium-exposed infants. **2. Why the Other Options are Incorrect:** * **B. Neural Tube Defects:** These (e.g., spina bifida) are primarily associated with **Valproate** and **Carbamazepine** due to their interference with folate metabolism. * **C. Renal Anomaly:** While lithium causes renal side effects in adults (like Nephrogenic Diabetes Insipidus), it is not the primary congenital concern. However, "Floppy Baby Syndrome" and neonatal hypothyroidism can occur if lithium is used near term. * **D. Fetal Hydantoin Syndrome:** This is a specific constellation of defects (cranial-facial abnormalities, hypoplastic nails/digits) caused by maternal use of **Phenytoin**. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Ratio:** The risk of Ebstein’s anomaly in the general population is 1 in 20,000; with lithium exposure, it increases to approximately 1 in 1,000. * **Management:** If a patient on lithium plans to conceive, the drug should ideally be tapered. If pregnancy is discovered, a **fetal echocardiogram** and Level II ultrasound are mandatory at 18–20 weeks. * **Breastfeeding:** Lithium is generally **avoided** during breastfeeding as it is excreted in high concentrations in breast milk, risking lithium toxicity in the neonate.

Q: What is the drug of choice for prophylaxis of mania?

Lithium. **Explanation:** **Lithium** is the gold-standard **Drug of Choice (DOC) for the prophylaxis of Bipolar Affective Disorder (BPAD)**, including both manic and depressive episodes. It is a mood stabilizer that effectively reduces the frequency and severity of relapses. For prophylaxis, therapeutic serum lithium levels are maintained between **0.6 – 0.8 mEq/L** (lower than the 0.8 – 1.2 mEq/L required for acute mania). **Analysis of Incorrect Options:** * **B. Haloperidol:** This is a typical antipsychotic used for the **acute management** of manic symptoms (agitation, psychosis) due to its rapid onset. However, it is not used for long-term prophylaxis as it does not stabilize mood and carries a high risk of Extrapyramidal Side Effects (EPS). * **C. Clozapine:** An atypical antipsychotic reserved for **treatment-resistant schizophrenia** or refractory mania. It is not a first-line prophylactic agent due to the risk of agranulocytosis. * **D. Carbamazepine:** An anticonvulsant used as a **second-line** mood stabilizer. It is preferred in "Rapid Cyclers" or patients who do not respond to Lithium, but it is not the primary DOC. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Lithium is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. * **Monitoring:** Before starting Lithium, check **Thyroid Function Tests (TFTs)** and **Renal Function Tests (RFTs)**, as it can cause hypothyroidism and nephrogenic diabetes insipidus. * **Narrow Therapeutic Index:** Lithium toxicity occurs >1.5 mEq/L; hemodialysis is the treatment of choice for severe toxicity (>3.5 mEq/L). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors can increase lithium levels, leading to toxicity.

Q: What is the drug of choice for a patient experiencing a manic episode of bipolar disorder?

Lithium. **Explanation:** **Lithium (Option A)** is the gold-standard treatment and the drug of choice for the management of acute manic episodes in Bipolar Affective Disorder (BPAD). It acts as a potent mood stabilizer by modulating neurotransmitters (decreasing dopamine and glutamate, increasing GABA) and inhibiting the inositol monophosphatase pathway. Beyond its efficacy in treating mania, Lithium is uniquely high-yield for its **anti-suicidal properties** and its role in long-term prophylaxis. **Why the other options are incorrect:** * **Amphetamine (Option B):** This is a CNS stimulant that increases synaptic dopamine. It can actually *precipitate* or worsen a manic episode and is contraindicated in BPAD. * **Diazepam and Alprazolam (Options C & D):** These are benzodiazepines. While they may be used as adjuncts to manage agitation or insomnia during mania, they do not treat the underlying mood pathology. They are not primary mood stabilizers. **High-Yield Clinical Pearls for NEET-PG:** 1. **Therapeutic Index:** Lithium has a narrow therapeutic index. For **acute mania**, the target serum level is **0.8–1.2 mEq/L**; for **maintenance**, it is **0.6–0.8 mEq/L**. 2. **Alternative:** If Lithium is contraindicated (e.g., renal failure), **Sodium Valproate** is the preferred alternative. 3. **Teratogenicity:** Lithium use during pregnancy is associated with **Ebstein’s Anomaly** (tricuspid valve malformation). 4. **Side Effects:** Common side effects include fine tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism.

Question 1

Which of the following statements is true about neuroleptic malignant syndrome?

Accepted Answer

General antipsychotics are more associated with its development.

Answer

Symptoms include rigidity, fever, and altered consciousness.

Answer

Dantrolene is an effective treatment for improving symptoms.

Answer

Bromocriptine can be used in the management of neuroleptic malignant syndrome.

Question 2

Which of the following antidepressants is used in atypical depression?

Accepted Answer

Phenelzine

Answer

Imipramine

Answer

Paroxetine

Answer

Amitriptyline

Question 3

Which of the following medications is least effective against depression?

Accepted Answer

Valproate

Answer

Lamotrigine

Answer

Lithium

Answer

Aripiprazole

Question 4

What is the usual adult maintenance dose of Clozapine?

Accepted Answer

300 mg

Answer

150 mg

Answer

250 mg

Answer

500 mg

Question 5

What is the most common congenital anomaly associated with lithium use during pregnancy?

Accepted Answer

Cardiac malformations

Answer

Neural tube defects

Answer

Renal anomaly

Answer

Fetal hydantoin syndrome

Question 6

What is the drug of choice for prophylaxis of mania?

Accepted Answer

Lithium

Answer

Haloperidol

Answer

Clozapine

Answer

Carbamazepine

Question 7

Which of the following modes of electrode placement is most commonly employed in ECT?

Accepted Answer

Bifrontotemporal

Answer

Bifrontal occipital

Answer

Bifrontal

Answer

Right unilateral

Question 8

What is the drug of choice for Mixed Depressive-Manic (MDM) episodes?

Accepted Answer

Lithium

Answer

Diazepam

Answer

Olanzapine

Answer

Carbamazepine

Question 9

Which drug is not effective in treating pediatric acute mania?

Accepted Answer

Oxcarbazepine

Answer

Lithium

Answer

Divalproex

Answer

Carbamazepine

Question 10

What is the drug of choice for a patient experiencing a manic episode of bipolar disorder?

Accepted Answer

Lithium

Answer

Amphetamine

Answer

Diazepam

Answer

Alprazolam

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?